Investigational drug · Phase 2
ENV-501
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ENV-501"
First trial start
2025
Dec 17, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ENV-501", any sponsor or status.
Conditions studied
As listed on its trial records.
- Melanoma (Skin)
- Non Small Cell Lung Cancer
- Breast Cancer
Approved drugs for the same conditions: Breast cancer · Small cell lung cancer · Melanoma · Oncology · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "ENV-501" as an intervention, largest first.
Hummingbird BioscienceIndustry
NCT06956690 · 180 participants (planned) · Start Dec 17, 2025 · Primary completion Jul 2027
Drug: ENV-501 · For: Melanoma (Skin); Non Small Cell Lung Cancer; Breast Cancer
Sites: La Jolla, California; Indianapolis, Indiana; Farmington Hills, Michigan · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Melanoma (Skin)
- BCD-217Phase 32 trials
Biocad · Melanoma Stage III, Melanoma (Skin), Melanoma
- prolgolimabBCD-100, FortecaPhase 31 trial
Biocad · Melanoma, Melanoma (Skin), Melanoma Stage III
- DNA VaccinePhase 22 trials
NEC Bio B.V · Triple Negative Breast Cancer, Malignant Melanoma, Melanoma (Skin)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.